Sarepta Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Sarepta Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- SRPT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000873303
Board of directors
-
Claude Nicaise · DirectorSince 2023
-
Douglas S. Ingram · Director · President & CEOSince 2023
-
Hans Lennart Rudolf Wigzell · DirectorSince 2023
-
Kathryn Jean Boor · DirectorSince 2023
-
M. Kathleen Behrens · DirectorSince 2023
-
Michael Andrew Chambers · DirectorSince 2023
-
Richard Barry · DirectorSince 2023
-
Stephen Mayo · DirectorSince 2023
Chief executives
Douglas S. Ingram
· President & CEO
Dates unknown
Board connections
6 of this board's directors also sit on 8 other boards.
- via Claude Nicaise and Richard Barry
- via Stephen Mayo
- via Claude Nicaise
- via Claude Nicaise
- via Kathryn Jean Boor
- via Stephen Mayo
- via M. Kathleen Behrens
- via Douglas S. Ingram
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 11, 2024 | Kathryn Jean Boor Director | Open-market sale | −761 | $122.93 | $93,550 |
| Mar 8, 2024 | Hans Lennart Rudolf Wigzell Director | Option exercise | +15,000 | $13.90 | $208,500 |
| Mar 8, 2024 | Hans Lennart Rudolf Wigzell Director | Open-market sale | −3,155 | $123.85 | $390,747 |
| Mar 8, 2024 | Arif Bilal Officer (Chief Tech Ops Officer) | Shares withheld for tax | −472 | $123.14 | $58,122 |
| Mar 8, 2024 | Rodino-Klapac Louise Officer (Head of R&D, CSO) | Shares withheld for tax | −909 | $123.14 | $111,934 |
| Mar 8, 2024 | Brown Ryan Edward Officer (EVP, General Counsel) | Shares withheld for tax | −899 | $123.14 | $110,703 |
| Mar 8, 2024 | Estepan Ian Michael Officer (Chief Financial Officer) | Shares withheld for tax | −1,035 | $123.14 | $127,450 |
| Mar 8, 2024 | Hans Lennart Rudolf Wigzell Director | Open-market sale | −11,745 | $123.10 | $1,445,810 |
| Mar 8, 2024 | Hans Lennart Rudolf Wigzell Director | Open-market sale | −100 | $122.39 | $12,239 |
| Mar 7, 2024 | Arif Bilal Officer (Chief Tech Ops Officer) | Shares withheld for tax | −506 | $120.49 | $60,968 |
| Mar 7, 2024 | Rodino-Klapac Louise Officer (Head of R&D, CSO) | Shares withheld for tax | −512 | $120.49 | $61,691 |
| Mar 7, 2024 | Brown Ryan Edward Officer (EVP, General Counsel) | Shares withheld for tax | −506 | $120.49 | $60,968 |
| Mar 7, 2024 | Estepan Ian Michael Officer (Chief Financial Officer) | Shares withheld for tax | −526 | $120.49 | $63,378 |
| Mar 5, 2024 | Stephen Mayo Director | Open-market sale | −3,135 | $122.96 | $385,480 |
| Mar 4, 2024 | Rodino-Klapac Louise Officer (Head of R&D, CSO) | Shares withheld for tax | −1,728 | $125.32 | $216,553 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.